

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-30 (Canceled).

Claim 31 (Previously Presented) A purified polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*.

Claim 32 (Previously Presented) The polypeptide according to claim 31, wherein said T epitope has an amino acid sequence selected from the group of the amino acid sequence of SEQ ID NOS: 39-46.

Claims 33-34 (Canceled).

Claim 35 (Previously Presented) The polypeptide of claim 31, further comprising at least one B epitope from a liver-stage specific protein produced by *P. falciparum*.

Claim 36 (Previously Presented) A vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of *P. falciparum* in the hepatic cells.

Claim 37 (Previously Presented) The vaccine composition directed against malaria according to claim 36, wherein said T epitope is selected from the group of an amino acid sequence of SEQ ID NOS: 39-42, an amino acid sequence of SEQ ID NOS: 43-46 and amino acid sequence of SEQ ID NO. 19.

Claim 38 (Canceled).

Claim 39 (Previously Presented) A synthetic polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*.

Claim 40 (New) A vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of *P. falciparum* in the hepatic cells, wherein said T epitope is selected from the group of an amino acid sequence of SEQ IS NOS: 39-42, an amino acid sequence of SEQ ID NOS: 43-46 and amino acid sequence of SEQ ID NO. 19.